A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Description: 

To compare the clinical benefit, as measured by the duration of OS, provided by BMS-936558 vs everolimus in subjects with advanced or metastatic renal cell carcinoma who have received prior anti-angiogenic therapy.

Study Number: 

PH 225212

Phase: 
III
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01668784

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.